If there is any positive news at all about ovarian cancer, it is this: It is more treatable than many other types of cancers, less likely to spread throughout the body beyond the abdomen and pelvis area, and often very responsive to aggressive chemotherapy treatment.
The central findings of research recently published in the medical journal JAMA Internal Medicine that focused on medical errors and misdiagnosis of illness conclude that misdiagnosis most frequently occurs very early in the doctor-patient encounter, often during an initial examination.
Statistics abound in the world of medical research. Some certainly come across as arid and academic to the general public, while others are underscored with immediate meaning and deep implications for medical care and patient safety.
Ironically, many of the things typically associated with medical malpractice -- such as a delayed diagnosis of cancer or the misdiagnosis of illness -- never actually result in a claim of hospital negligence at all.
The ability of scientists or research teams to replicate or otherwise test and evaluate the results of scientific studies authored by other parties is critical for a number of reasons.
It is no secret to many people who have gone to an emergency room for treatment in the past few years that ERs have become increasingly frantic and busy places.
A misreading of a nucleic acid test performed on a deceased donor's tissue has turned out to be a costly misdiagnosis resulting in at least four instances of donees becoming infected with the hepatitis C virus.
If you are an optimist who thinks that medical care and the country's overall state of health is progressively improving, you are, sadly, mistaken.
The subject matter was very clear and the related warning dire at the annual meeting of the American College of Chest Physicians (CHEST) in Honolulu recently: Dual standards for evaluating chronic obstructive pulmonary disease (COPD) are leading to misdiagnosis and improper treatment for many patients.
The time-honored advice of urologists and many advocacy groups recommending that men have a PSA blood test annually to screen for cancer is under siege and has been strongly challenged in recent years by a number of medical experts and organizations.